• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Klaus Dugi - Articles and news items

Boehringer Ingelheim logo

European Commission grants Lilly and Boehringer Ingelheim’s insulin glargine product marketing authorisation in Europe

Industry news / 10 September 2014 / Boehringer Ingelheim

The European Commission granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim’s insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above…

Boehringer Ingelheim logo

New Pradaxa® data to be presented during the American College of Cardiology’s 63rd Annual Scientific Session

Industry news / 24 March 2014 / Boehringer Ingelheim

Boehringer Ingelheim has announced that new findings from ongoing Pradaxa® research will be presented during the American College of Cardiology’s 63rd Annual Scientific Session…

Boehringer Ingelheim logo

Phase III data show Boehringer Ingelheim’s faldaprevir* was highly effective in a broad range of patients with genotype-1 hepatitis C

Industry news / 2 November 2013 / Boehringer Ingelheim

“These data are encouraging and reinforce the potential benefits of faldaprevir* as an effective treatment…”

Boehringer Ingelheim logo

New data show Striverdi® (olodaterol)* Respimat® improves exercise tolerance in patients with moderate to very severe COPD

Industry news / 29 October 2013 / Boehringer Ingelheim

“Exercise is an essential component of COPD management…”

Boehringer Ingelheim logo

New efficacy and safety data adds to evidence suppoith afatinib*(GIOTRIF®) in Asian and non-Asian lung cancer patients

Industry news / 27 October 2013 / Boehringer Ingelheim

“The new sub-analysis confirms the consistent safety profile of afatinib in Asian patients…”

Boehringer Ingelheim logo

New once-daily Striverdi* (olodaterol) Respimat® gains approval in first EU countries

Industry news / 18 October 2013 / Boehringer Ingelheim

“The improvements in lung function and quality of life seen with once-daily Striverdi® Respimat® are remarkable…”

Boehringer Ingelheim logo

Boehringer Ingelheim broadens efforts for interferon-free hepatitis C treatments through clinical collaboration with Presidio Pharmaceuticals

Industry news, News / 10 September 2013 / Boehringer Ingelheim

Boehringer Ingelheim announced the completion of patient enrolment for a Phase IIa clinical trial…

Boehringer Ingelheim logo

Phase III results: Once daily olodaterol* Respimat® provides effective and sustained improvements in lung function in patients with COPD1-3

Industry news, News / 9 September 2013 / Boehringer Ingelheim

Data from two 48 week Phase III studies involving more than 3,000 patients…

Boehringer Ingelheim logo

Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim’s innovation promise in cardiovascular diseases

Industry news, News / 3 September 2013 / Boehringer Ingelheim

Boehringer Ingelheim announces new plans to expand body of evidence for Pradaxa®…

Boehringer Ingelheim logo

ESC Congress 2013: New data provide evidence for the positive safety and efficacy profile of Pradaxa® in various atrial fibrillation patient populations

Industry news, News / 26 August 2013 / Boehringer Ingelheim

Boehringer Ingelheim announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013…

Boehringer Ingelheim logo

Phase III safety and efficacy data of Trajenta® (linagliptin) in elderly people with Type 2 Diabetes published in The Lancet

Industry news, News / 15 August 2013 / OgilvyHealthPR London

Linagliptin demonstrated clinically important HbA1c reduction, safety and tolerability profile in elderly people with Type 2 Diabetes with inadequate glycaemic control…

Boehringer Ingelheim logo

Boehringer Ingelheim announces full patient enrolment for two of its pivotal Phase III interferon-free hepatitis C clinical trials

Industry news, News / 15 August 2013 / Boehringer Ingelheim

Boehringer Ingelheim announced that enrolment of over 950 treatment naïve genotype-1b patients in the pivotal Phase III interferon-free HCVerso™ 1 and 2 trials is complete…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +